Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × melflufen × Plasma cell × Clear all

Phase

Status

Terminated 5 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 345 Bortezomib 223 Lenalidomide 187 Cyclophosphamide 165 Melphalan 157 Calcium Dobesilate 100 Peripheral Blood Stem Cell Transplantation 83 fludarabine phosphate 74 Thalidomide 71 Filgrastim 67 carfilzomib 56 pomalidomide 55 Granulocyte Colony-Stimulating Factor 53 Busulfan 53 daratumumab 51 ixazomib 50 Whole-Body Irradiation 50 Mycophenolic Acid 48 fludarabine 46 Prednisone 46 Tacrolimus 42 Cyclosporine 41 Antilymphocyte Serum 30 dexamethasone acetate 29 Radiotherapy 26 Etoposide 25 plerixafor 23 dexamethasone 21-phosphate 23 Bendamustine Hydrochloride 23 Stem Cell Transplantation 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02963493 2022-11-22

HORIZON

Oncopeptides AB

Phase 2 Completed

157 enrolled 26 charts 1 FDA

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡